Why investors aren’t excited about GSK’s $11bn Nuvalent deal Investors Chronicle 3d Pharma FTSE 100 Article paywall
The Zacks analyst blog highlights Gilead sciences, Merck and GSK Zacks 2d FDA Merck and Co Gilead Sciences
Aurobindo Pharma clears key US hurdle in Lannett acquisition, closing expected soon The Times of India 6h Biotech
U.S. Supreme Court Weighs In on "Skinny Labels" and Inducement JD Supra 14h Patent Law Intellectual Property South Carolina
US FTC imposes divestment condition on Aurobindo Pharma's $250 mn Lannett acquisition The Times of India 16h Biotech
Executives On The Move: Three CEOs, Four CMOs And Five CFOs Among This Week’s Changes Scrip Pharma Intelligence 18h
